Yael Cohen - Vascular Biogenics Vice President - Clinical Development
| VBLTDelisted Stock | USD 0.28 0.01 3.45% |
President
Dr. Yael Cohen serves as Vice President Clinical Development at Vascular Biogenics Ltd since 2008. Her work experience includes various roles at Gamida Cell Ltd, Merck Co. and Merck Research Labs . Dr. Cohen holds a Doctorate of Medicine degree from the Sackler Medical School at Tel Aviv University and has completed her residency in Internal Medicine at the Chaim Sheba Medical Center at Tel Hashomer, Israel, and a fellowship in Hematology at the Rabin Medical Center, Petach Tikva, Israel. Dr. Cohen is a Senior Physician at the Hematology Department at the Sourasky Medical Center, Tel Aviv, Israel. since 2008.
| Age | 60 |
| Tenure | 16 years |
| Phone | 972 8 993 5000 |
| Web | https://www.vblrx.com |
Vascular Biogenics Management Efficiency
The company has return on total asset (ROA) of (0.2912) % which means that it has lost $0.2912 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5952) %, meaning that it created substantial loss on money invested by shareholders. Vascular Biogenics' management efficiency ratios could be used to measure how well Vascular Biogenics manages its routine affairs as well as how well it operates its assets and liabilities.Vascular Biogenics currently holds 564 K in liabilities with Debt to Equity (D/E) ratio of 0.05, which may suggest the company is not taking enough advantage from borrowing. Vascular Biogenics has a current ratio of 3.97, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Vascular Biogenics' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Found 5 records | PRESIDENT Age | ||
| Srinivas Subramanian | Avenue Therapeutics | 53 | |
| James Doherty | Acumen Pharmaceuticals | 56 | |
| Erin MD | Terns Pharmaceuticals | 53 | |
| Kelly Carranza | Acumen Pharmaceuticals | N/A | |
| Robert Lisicki | Zura Bio Limited | 56 | |
Management Performance
| Return On Equity | -0.6 | |||
| Return On Asset | -0.29 |
Vascular Biogenics Leadership Team
Elected by the shareholders, the Vascular Biogenics' board of directors comprises two types of representatives: Vascular Biogenics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Vascular. The board's role is to monitor Vascular Biogenics' management team and ensure that shareholders' interests are well served. Vascular Biogenics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Vascular Biogenics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Samuel Backenroth, Chief Officer | ||
| Naamit Sher, VP of Devel. and Regulatory | ||
| Yael Cohen, Vice President - Clinical Development | ||
| Erez MBA, Sr Operations | ||
| Eyal Breitbart, Vice President Research | ||
| Deborah Scott, Managing Communications | ||
| Pr MD, CEO Director | ||
| Advocate Horn, G Counsel | ||
| Tami MD, VP Devel |
Vascular Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Vascular Biogenics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.6 | |||
| Return On Asset | -0.29 | |||
| Operating Margin | (33.89) % | |||
| Current Valuation | (10.99 M) | |||
| Shares Outstanding | 77.64 M | |||
| Shares Owned By Insiders | 13.48 % | |||
| Shares Owned By Institutions | 14.00 % | |||
| Number Of Shares Shorted | 250.34 K | |||
| Price To Earning | (9.32) X | |||
| Price To Book | 0.35 X |
Thematic Opportunities
Explore Investment Opportunities
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Other Consideration for investing in Vascular Stock
If you are still planning to invest in Vascular Biogenics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Vascular Biogenics' history and understand the potential risks before investing.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |